RuDi Bio Announces Over RMB 100 Million Series B+ Financing to Accelerate Clinical Development and Commercialization of Nanosecond Pulsed Electric Field Technology

VCBeat has learned that Hangzhou Ruidi Biotechnology Co., Ltd. (hereinafter referred to as “Ruidi Biotech” or the “Company”) has completed a Series B+ financing round exceeding RMB 100 million. This round of financing was led byZhangjiang Suifeng Phase II Fund, managed by Zhang JianghaohengandMr. He Haichao, Chairman of Jinwei Machinery and Jinwei FundJoint Investment.

This round of financing will help further accelerate the clinical trials and commercialization of multiple products developed by the company based on its nanosecond pulsed electric field technology platform. Previously, Ruidi Biotechnology had successfully secured angel funding from Proxima, Series A funding led by Taiyu Investment, and Series B funding co-led by Jifeng Capital and Tailong Investment.

With the continuous advancement of high-power pulsed electric field technology, its applications in the medical device sector have continued to expand, particularly in oncology, cardiology, respiratory medicine, vascular surgery, neurology, and brain-computer interfaces. Leveraging a decade of technological expertise and hundreds of patents, Hangzhou Ruidi Biotechnology Co., Ltd. has solidified its leading position in the global nanosecond pulse technology field. Its ultra-high-voltage, ultra-short nanosecond pulse technology is regarded as a strong contender for next-generation ablation therapies, owing to its superior tissue selectivity, rapid energy delivery, and highly effective lesion formation.

Through robust original innovation and translational research, Hangzhou Ruidi Biotechnology Co., Ltd. has conducted multicenter clinical trials, providing ample evidence-based medical support for the clinical application of this technology. Its steep pulse ablation system (nanosecond pulse ablation system) has not only received market approval from China’s National Medical Products Administration but has also been designated as a “Breakthrough Device” by the U.S. FDA, becoming the first pulsed field ablation product in China to receive this distinction.

Supported by multiple major national research initiatives, the Pulsed Electric Field Medical Translation Laboratory at Hangzhou Ruidi Biotechnology Co., Ltd. continues to expand the medical applications of pulsed electric field technology, including enhancing the delivery of immunotherapeutic agents, controlling the release of chemotherapeutic drugs, optimizing electrochemical intervention for biomolecules, and stimulating the growth of bone or skin tissues.

Meanwhile, Hangzhou Ruidi Biotechnology Co., Ltd. has established multiple product pipelines, further expanding the indications for its products and applying pulsed electric field technology to a broader range of areas, thereby continuously exploring new markets. The company’s technological upgrades, growing clinical demand, and attention from prominent investors collectively demonstrate the clinical value and broad market prospects of nanosecond pulsed electric field ablation technology.

Zhangjiang Haoheng is an equity investment firm initiated by Zhangjiang Hi-Tech (600895.SH). Its investment portfolio spans sectors including integrated circuits, biopharmaceuticals and medical devices, next-generation information technology, and intelligent manufacturing, with assets under management exceeding RMB 3 billion.Chu Xiaofei, Head of the Biopharmaceutical Group at Zhangjiang HaohengIt stated: “Since Boston Scientific, Medtronic, and Johnson & Johnson launched their pulsed field ablation (PFA) systems, numerous renowned international companies have dedicated themselves to the research and development of products based on microsecond pulsed electric field technology. Adhering to independent innovation, Hangzhou Ruidi Biotechnology Co., Ltd. has introduced its third-generation nanosecond pulsed technology, continuing to innovate in the field of energy-based interventional devices. Clinical trial results of its products have also demonstrated the superiority of its technology. We hope that Ruidi Biotechnology can accelerate the clinical and commercialization processes of its products, so that a broad patient population may benefit at the earliest possible time.”

Mr. He Haichao, Chairman of Jinwei Machinery and Jinwei Fund“The nanosecond pulsed technology, as a globally leading innovative therapy, has gained high recognition from regulatory authorities both in China and abroad in the field of tumor treatment. Ruidi Biotechnology’s nanosecond steep pulse ablation system, being the only malignant tumor ablation product worldwide to simultaneously receive dual innovation channel certifications from China and the United States, marks a significant breakthrough in minimally invasive interventional tumor treatment technologies. Jinwei Fund is delighted to collaborate with Ruidi’s team of scientists and physicians, providing financial support to help Ruidi refine its domestic brand, while leveraging Jinwei Machinery’s global experience to assist Ruidi in expanding into international markets. The journey ahead is long and challenging; we are committed to helping Chinese medical devices achieve major breakthroughs at the forefront of the international arena.”